Poster Session

P68. Evaluation of the benefits of a newly marketed vaginal gel (palomacarer) on vaginal health of peri and postmenopausal women (atrovag survey)

Santiago Palacios (ES), Fernando Losa (ES)

[Palacios] Instituto Palacios de Salud y Medicina de la Mujer, [Losa] Clínica Sagrada Família

Context Genitourinary syndrome causes significant discomfort and deterioration of the quality of life among peri- and postmenopausal patients. In any product that is administered vaginally, periodic evaluation of the advantages, disadvantages, effects and benefits perceived by prescribers and users can help to improve the habits and conditions of its prescription and use, and as consequence, the adherence and the effectiveness. Even more when the product has a novel formulation and it has relatively little time available in pharmacies. PalomacareR is a multi-ingredient medical device marketed in Spain since July 2015, which is applied as a vaginal gel. It has moisturizing and restorative properties of the vaginal mucosa and is indicated for the improvement of symptoms and signs that make up the genitourinary syndrome. Objectives. The objective of this survey was to know the perception of the PalomacareR effectiveness that have both the prescribing physicians and peri and postmenopausal women after almost two years of commercialization. Methods The Atrovag survey was conducted during the first quarter of 2017. A questionnaire of 10 questions (8 one choice and 2 with multiple choice) related to the perceptions of PalomacareR in clinical practice was addressed to Spanish gynaecologists who were visiting women who already were using PalomacareR. A second questionnaire of 5 questions (4 one choice and 1 with multiple choice) was addressed to women. A double entry of information in Excel file was performed to assure the quality of the data. Results A total of 143 doctors participated in the survey, 99% of whom with 5 or more patients using PalomacareR. 53% of the survey respondents indicated an improvement of vaginal dryness in more than 80% of women. An improvement in quality and no or less pain in sexual relations was point out by 80% of doctors. Vaginal elasticity, moisture and epithelial integrity were vaginal health parameters with a significant improvement according to 38%, 24% and 17% of participants, respectively. Finally, 86% of the doctors said that no patient had reported any adverse effect. Stinging/burning was the most adverse effect indicated by the participants (6%) followed by itching/Irritation and sensation of product lost (4% each). Out of 418 participant women, 73% used no successful previous treatments, and 96% and 93% considered PalomacareR effectiveness as good or excellent, and better or much better than previous treatments, respectively. Conclusions PalomacareR is a product with a good effectiveness and tolerance perception, that make it highly satisfactory by prescribers and considered better than other previous treatments by their users.